Accessibility Tools
Learn about ADHD and Mental Health. Causes, symptoms, treatment. We help you identify learning disabilities.
MPR > News > Drugs In The Pipeline > Novel DNRI Agent Improves ADHD Symptoms In Study Da Hee Han, PharmD April 21, 2017 Sunovion announced positive Phase 3 study data (SEP360-305) for dasotraline being evaluated in patients aged 6–12 years with attention deficit hyperactivity disorder (ADHD). The findings were presented at the 6th World Congress on ADHD in…
According to the National Institute of Health and research studies, toxic chemical exposures may play a role in learning and developmental disabilities. The exposure prenatal and during early childhood to certain chemicals may cause a disruption in normal neurological development or function that can last a lifetime. Through scientific studies the following chemicals, although not…